Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kechang Granules is a Traditional Chinese Medicine (TCM) candidate developed by Hangzhou Wang Changgen Liver, Gallbladder, and Kidney Traditional Chinese Medicine Technology Co., Ltd. for the treatment of acute bronchitis. It is specifically formulated to address the 'wind-heat invading the lung' syndrome, a common TCM diagnosis for respiratory infections characterized by cough, fever, and yellow sputum. The granules are designed to clear heat, resolve phlegm, and suppress cough. The drug has been evaluated in Phase II clinical trials in China (e.g., CTR20191445) to establish its safety and therapeutic efficacy compared to placebo. As a multi-herb TCM formulation, it likely exerts its effects through a multi-targeted approach involving anti-inflammatory and antitussive mechanisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kechang Granules.